Sangamo Therapeutics Inc. (SGMO)

11.07
0.22 2.00
NASDAQ : Health Technology
Prev Close 10.85
Open 10.73
Day Low/High 10.68 / 11.14
52 Wk Low/High 6.26 / 17.35
Volume 331.51K
Avg Volume 1.69M
Exchange NASDAQ
Shares Outstanding 115.67M
Market Cap 1.29B
EPS -0.70
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

Sangamo Therapeutics Announces Participation At Upcoming Investor Conferences

Sangamo Therapeutics Announces Participation At Upcoming Investor Conferences

Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, announced today that CEO Sandy Macrae will present at the 2019 Wedbush PacGrow Healthcare Conference in New York City.

Sangamo Therapeutics Appoints Gary H. Loeb As Executive Vice President And General Counsel

Sangamo Therapeutics Appoints Gary H. Loeb As Executive Vice President And General Counsel

Sangamo Therapeutics, Inc. (NASDAQ: SGMO), a genomic medicine company, announced today the appointment of Gary H.

Sangamo Therapeutics Announces Second Quarter 2019 Conference Call And Webcast

Sangamo Therapeutics Announces Second Quarter 2019 Conference Call And Webcast

Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, announced today that the Company will release its second quarter 2019 financial results after the market closes on Wednesday, August 7, 2019.

Sangamo Announces Nature Biotechnology Publication Of New Strategies For Optimizing The Specificity Of Gene Editing Nucleases

Sangamo Announces Nature Biotechnology Publication Of New Strategies For Optimizing The Specificity Of Gene Editing Nucleases

Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, announced today the publication in Nature Biotechnology of a manuscript by Jeffrey Miller, Ph.

Sangamo Shares Soar as Hemophilia Drug Shows Promise

Sangamo Shares Soar as Hemophilia Drug Shows Promise

Sangamo's stock price is surging after a pair of patients reported no bleeding events for as long as 24 weeks following treatment following investigational SB-525 gene therapy for severe hemophilia A.

Sangamo And Pfizer Announce Updated Phase 1/2 Results For SB-525 Investigational Hemophilia A Gene Therapy Showing Sustained Increased Factor VIII Levels

Sangamo And Pfizer Announce Updated Phase 1/2 Results For SB-525 Investigational Hemophilia A Gene Therapy Showing Sustained Increased Factor VIII Levels

Sangamo Therapeutics, Inc. (NASDAQ: SGMO), a genomic medicine company, and Pfizer, Inc.

 Sangamo Therapeutics Announces Nature Medicine Publication Detailing The Activity Of Disease Allele-Selective Zinc Finger Proteins In Preclinical Models Of Huntington's Disease

 Sangamo Therapeutics Announces Nature Medicine Publication Detailing The Activity Of Disease Allele-Selective Zinc Finger Proteins In Preclinical Models Of Huntington's Disease

Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, today announced the publication of a manuscript describing the activity of allele-selective zinc finger protein transcription-factors (ZFP-TFs) in preclinical models of Huntington's...

Sangamo Announces Upcoming Presentation Of Investigational SB-525 Hemophilia A Gene Therapy Data At ISTH 2019

Sangamo Announces Upcoming Presentation Of Investigational SB-525 Hemophilia A Gene Therapy Data At ISTH 2019

BRISBANE, Calif., June 21, 2019 /PRNewswire/ -- Sangamo Therapeutics, Inc.

Sangamo Therapeutics Announces Presentations At Upcoming Scientific, Medical And Investor Conferences

Sangamo Therapeutics Announces Presentations At Upcoming Scientific, Medical And Investor Conferences

Hemophilia A SB-525 gene therapy clinical data accepted for oral presentation at ISTH

Sangamo Therapeutics Announces Participation In The Bank Of America Merrill Lynch 2019 Health Care Conference

Sangamo Therapeutics Announces Participation In The Bank Of America Merrill Lynch 2019 Health Care Conference

BRISBANE, Calif., May 10, 2019 /PRNewswire/ -- Sangamo Therapeutics, Inc.

Sangamo Therapeutics Reports First Quarter 2019 Financial Results

Sangamo Therapeutics Reports First Quarter 2019 Financial Results

Conference Call and Webcast Scheduled for 5:00 p.m. Eastern Time

Sangamo Therapeutics Announces First Quarter 2019 Conference Call And Webcast

Sangamo Therapeutics Announces First Quarter 2019 Conference Call And Webcast

BRISBANE, Calif., May 1, 2019 /PRNewswire/ -- Sangamo Therapeutics, Inc.

10 Speculative Stock Plays in the Biotech Sector

10 Speculative Stock Plays in the Biotech Sector

For investors interested in biotech, there's a lot to choose from, with options ranging from startups with potentially blockbuster new treatments to companies those that have been around the block a few times.

Sangamo Therapeutics Announces Presentations At 2019 Annual Meeting Of The American Society Of Gene & Cell Therapy

Sangamo Therapeutics Announces Presentations At 2019 Annual Meeting Of The American Society Of Gene & Cell Therapy

BRISBANE, Calif., April 15, 2019 /PRNewswire/ -- Sangamo Therapeutics, Inc.

Sangamo Therapeutics Announces Pricing Of Public Offering Of Common Stock

Sangamo Therapeutics Announces Pricing Of Public Offering Of Common Stock

RICHMOND, Calif., April 4, 2019 /PRNewswire/ -- Sangamo Therapeutics, Inc.

Sangamo Therapeutics Announces Proposed Public Offering Of Common Stock

Sangamo Therapeutics Announces Proposed Public Offering Of Common Stock

RICHMOND, Calif., April 3, 2019 /PRNewswire/ -- Sangamo Therapeutics, Inc.

I Have My Eye on This Warren Buffett Stock Amid the Choppy Action

I Have My Eye on This Warren Buffett Stock Amid the Choppy Action

Market players are more skeptical of the quick moves on U.S.-China trade news.

5 Stocks on My Radar During a Quiet Day

5 Stocks on My Radar During a Quiet Day

Sometimes dull action like this can be good for trading.

Sangamo Stock Soars on Positive Hemophilia Treatment Trial

Sangamo Stock Soars on Positive Hemophilia Treatment Trial

The stock surges on 'encouraging' results from a genome-therapy trial for the treatment of a severe type of hemophilia.

Sangamo And Pfizer Announce Phase 1/2 Interim Data For Investigational Hemophilia A Gene Therapy

Sangamo And Pfizer Announce Phase 1/2 Interim Data For Investigational Hemophilia A Gene Therapy

- Eight patients treated with SB-525 gene therapy showed dose-dependent increases in FVIII activity, with the two patients treated with the 3e13 vg/kg dose reaching normal FVIII levels

Sangamo Announces Agreement Securing Access To Large-Scale, Commercial-Grade Manufacturing Capacity At Brammer Bio

Sangamo Announces Agreement Securing Access To Large-Scale, Commercial-Grade Manufacturing Capacity At Brammer Bio

- Balanced in-house and contract manufacturing strategy to provide clinical and commercial supply for Sangamo's growing pipeline of AAV-based genomic therapies

Sangamo And Pfizer Announce Phase 1/2 Interim Data For Investigational Hemophilia A Gene Therapy

Sangamo And Pfizer Announce Phase 1/2 Interim Data For Investigational Hemophilia A Gene Therapy

Sangamo Therapeutics, Inc. (NASDAQ: SGMO), a genomic medicine company, and Pfizer, Inc.

Sangamo Provides Clinical Development Update Including Early Phase 1/2 Beta Thalassemia Gene-edited Cell Therapy Data

Sangamo Provides Clinical Development Update Including Early Phase 1/2 Beta Thalassemia Gene-edited Cell Therapy Data

‒ Conference call and webcast scheduled for 8:00 a.m. Eastern Time today

Sangamo Therapeutics To Host April 2, 2019 Conference Call To Provide Clinical Update

Sangamo Therapeutics To Host April 2, 2019 Conference Call To Provide Clinical Update

BRISBANE, Calif., April 1, 2019 /PRNewswire/ -- Sangamo Therapeutics, Inc.

Sangamo Therapeutics Presents New Preclinical Data Demonstrating Significant Reduction In Tau Expression With Gene Regulation Technology

Sangamo Therapeutics Presents New Preclinical Data Demonstrating Significant Reduction In Tau Expression With Gene Regulation Technology

- Sangamo's gene regulation platform technology fuses zinc finger proteins with transcription factors (ZFP-TFs)

Interesting SGMO Put And Call Options For November 15th

Interesting SGMO Put And Call Options For November 15th

Investors in Sangamo Therapeutics Inc saw new options begin trading this week, for the November 15th expiration. One of the key data points that goes into the price an option buyer is willing to pay, is the time value, so with 241 days until expiration the newly trading contracts represent a potential opportunity for sellers of puts or calls to achieve a higher premium than would be available for the contracts with a closer expiration.

Notable Thursday Option Activity: SGMO, SKX, CLF

Notable Thursday Option Activity: SGMO, SKX, CLF

Among the underlying components of the Russell 3000 index, we saw noteworthy options trading volume today in Sangamo Therapeutics Inc , where a total of 21,510 contracts have traded so far, representing approximately 2.2 million underlying shares. That amounts to about 128.3% of SGMO's average daily trading volume over the past month of 1.7 million shares.

TheStreet Quant Rating: D+ (Sell)